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Case Series
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ABSTRACT
Background: Limited information is available about long-term pamidronate 
treatment in adults with fibrous dysplasia (FD) of bone.
Objective: The aim of this case series was to report the clinical outcomes and 
the biochemical and densitometric findings in a group of young adult patients with 
polyostotic FD treated for ≥3 years with IV pamidronate.
Methods: Pamidronate was administered every 6 months (60 mg/d for 3 days) 
for 2 years. Thereafter, treatment was individualized. Pamidronate was administered 
at shorter or longer intervals based on response. Bone pain, radiography, serum bone 
alkaline phosphatase (BALP) activity, and urinary C-terminal cross-linking telopep-
tide of type I collagen (CTX-I) concentration were assessed for a mean of 7 years. Bone 
mineral density (BMD) of FD areas (FDas) and contralateral areas (CLas) were measured 
at baseline and at 12 and 24 months. Data were collected prospectively.
Results: Seven patients (5 women, 2 men; mean [SD] age, 31.0 [7.2] years 
[range, 22–43 years]) were included in the study. Patients received IV pamidronate 
for a mean of 6.9 years (median, 7.1 years [range, 3.7–10.9 years]). Pamidronate was 
associated with a reduction in bone pain and a significant reduction in BALP in all 
patients at the end of follow-up (P < 0.02). The mean reduction from baseline in 
CTX-I concentration (measured in 3 patients) was 56%; this difference was not sig-
nificant. Mean BMD values of FDas were significantly increased at 12 months (by 
5.9%; P < 0.05) compared with baseline; but was not significantly increased at 
24 months (7.3%), probably reflecting a higher dispersion of values due to individual 
responses to treatment. No significant changes were observed in CLa BMDs. Mean 
BMD of FDa had a numerically lower decrease of 15.3% compared with CLa at base-
line; these decreases with pamidronate were 10.8% at 12 months (P = NS) and 9.3% 
at 24 months (P < 0.05). Refilling of osteolytic lesions was not observed.
Conclusions: These patients with FD of bone treated with IV pamidronate 
long term had improvement in bone pain and BMD. The effectiveness of individual-
ized pamidronate administration in the long-term treatment of FD in adult patients 
should be investigated in blinded controlled trials. (Curr Ther Res Clin Exp. 2009;70: 
161–172) © 2009 Excerpta Medica Inc.
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INTRODUCTION
Over the past 10 years and since the first report in 1994 by Liens et al1 suggesting 
that pamidronate might be associated with improvement in the clinical features of 
fibrous dysplasia (FD), several patient series and case reports, including both adults1–9 
and children,10–17 have been published. IV pamidronate treatment in patients with 
FD of bone has been reported to reduce bone pain and markers of bone turnover, im-
prove the radiographic appearance of lesions, and increase bone mineral density 
(BMD) of affected areas.1–17 Radiographic evidence of improvement was reported in 
50% of the patients in some of these studies,1,2,4,7,8,12,17 but the percentage of patients 
showing such improvement was not as high in other studies.3,5,6,9–11,13–16 
Information regarding tolerability and effectiveness after long-term (≥3-year) pami- 
dronate treatment in adults is limited.9 According to Chapurlat,9 treatment with 
pamidronate has been found to be well tolerated, reduce increased osteoclastic activity 
in FD, and probably improve bone pain, but further randomized controlled trials are 
needed.
The aim of this case series was to report the clinical outcomes and the biochemical 
and densitometric findings in a group of young adult patients with polyostotic FD 
treated for ≥3 years with IV pamidronate.
MATERIALS AND METHODS
Patients
Data from patients aged 15 to 38 years, with a confirmed diagnosis of FD and 
hospitalized between 1996 and 2007 at the Bone Metabolic Disease Unit of Buenos 
Aires University Hospital (Buenos Aires, Argentina), a referral center for patients 
with rare bone diseases, were included. During this extended period, pamidronate 
therapy was administered to those patients with concentrations of bone turnover 
markers above the upper limit of normal (normal values, serum bone alkaline phos-
phatase [BALP] = 31–95 IU/L and urinary C-terminal cross-linking telopeptide of 
type I collagen [CTX-I] = 10–400 μg/mmol creatinine) and with bone pain related 
to the disease. A total of 16 patients were treated. Treatment was stopped when con-
centrations of bone turnover markers remained in the normal range and no bone pain 
was reported.
To evaluate the long-term response to pamidronate therapy in young adult patients 
with FD, registered data from the 7 patients who were treated for ≥3 years with 
pamidronate were reported. Data were collected prospectively.
The results from patients 1, 4, 6, and 7 at 1 year of pamidronate treatment were 
previously published in a 2-year prospective study7 of the effect of pamidronate 
(180 mg every 6 months) on bone turnover markers and local BMD.
After concluding this initial study, all patients with FD at our referral center 
signed an informed consent form before starting treatment with IV pamidronate. 
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Data were recorded in keeping with a protocol approved by the ethics committee of 
Buenos Aires University Hospital. This protocol standardized the long-term follow-
up of FD patients treated with pamidronate, as described. 
Pamidronate Treatment
Based on previous reports,1,2,18 pamidronate 180 mg (60 mg/d for 3 consecutive 
days) was administered intravenously every 6 months for the first 2 years of treatment. 
All patients received calcium and vitamin D supplementation.
Due to variability among patients in their responses to pamidronate treatment 
(reduction in bone pain and decrease in values of bone turnover markers), the interval 
between pamidronate cycles was lengthened or shortened after 2 years of therapy. The 
interval between pamidronate cycles was shortened to 3 months if the following 
occurred: relapse, defined as no reduction or increase in bone pain severity according 
to bone pain severity criteria (severe, moderate, mild, or asymptomatic); and/or an 
increase in bone turnover marker concentrations (higher levels or levels above the 
normal range in ≥1 bone turnover marker) was observed compared with the most 
recent previous evaluation. Conversely, the next pamidronate cycle was postponed 
3 months only if both no bone pain was reported and previously high bone marker 
values were found to have reached normal values. 
Clinical Follow-Up
All patients were evaluated every 3 months. Severity of bone pain was assessed using 
the following criteria7: severe = unbearable or continuous bone pain with or without im-
paired mobility; moderate = bearable bone pain and/or impaired mobility; mild = inter-
mittent episodes of bone pain without impaired mobility; and asymptomatic = no bone 
pain or altered mobility. Adverse events were recorded at each clinical visit. 
Biochemical Determinations
Serum and 24-hour urine samples were collected at baseline and at regular intervals 
(every 3 months). Serum calcium, 25-hydroxyvitamin D, phosphate, and creatinine; 
total alkaline phosphatase; and urinary calcium, phosphorus, and creatinine values were 
determined using standard techniques. Serum 25-hydroxyvitamin D concentrations 
were determined using radioimmunoassay (DiaSorin, Inc., Stillwater, Minnesota). Inter-
assay and intra-assay %CVs were 19.0% and 7.6%, respectively. Serum parathyroid 
hormone concentration was measured by radioimmunoassay using an antiserum that 
recognizes the mid- to carboxy-terminal portions of the molecule. BALP activity was 
measured using selective wheat germ lectin precipitation.19 Urinary CTX-I was mea-
sured using a competitive enzyme immunoassay method (Crosslaps Osteometer A/S, 
Rodrove, Denmark). Urinary excretion was corrected for creatinine values. To evaluate 
the presence of phosphate wasting, fractional excretion of phosphorus was calculated.20
Bone Mineral Density
Total skeleton BMD was assessed using dual-energy x-ray absorptiometry (DEXA). 
We reported the BMD results from the 5 patients (patients 1, 4, 5, 6, and 7) for whom 
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the same DEXA equipment was used to make all measurements. Due to fiscal con-
straints, however, the DEXA equipment was no longer available at the institution, 
resulting in the availability of data from the first 2 years of treatment only for com-
parison. Using baseline radiographs and bone scintigraphy, the BMD of long bones 
affected with areas of FD (FDas) was determined using a region-of-interest program. 
This method has been previously described by Parisi et al7 and others.21–23 To mini-
mize interobserver variation, all analyses were made by the same technical expert. 
BMDs of FDas were compared with the contralateral areas (CLas). The difference in 
BMD between FDas and CLas was calculated as a percentage; the CLa value was con-
sidered to be 100%.
Radiography
Radiographs of affected areas were obtained before treatment commencement and 
annually thereafter.
Statistical Analysis
Statistical analysis was performed using the SPSS version 13.0 (SPSS Inc., Chicago, 
Illinois). BMD and biochemical data obtained at each follow-up visit were compared 
with baseline values using the Wilcoxon signed rank test and were expressed as a 
percentage of variation. The difference between FDa and CLa was expressed as a per-
centage and compared using the Wilcoxon signed rank test. A value of P < 0.05 was 
considered significant.
RESULTS
Seven patients (5 women, 2 men; mean [SD] age at the end of follow-up, 31.0 [7.2] years 
[range, 22–43 years]) were included in the study. Patients were treated with IV 
pamidronate for a mean of 6.9 years (median, 7.1 years [range, 3.7–10.9 years]). All 
patients had a diagnosis of polyostotic FD confirmed on bone biopsy. The character-
istics of the patients are listed in the table. 
All patients reported bone pain associated with FD lesions at baseline. Irrespective 
of disease severity, pamidronate treatment reduced bone pain criteria from baseline in 
all patients (Table), and none of the patients reported a new fracture throughout the 
follow-up period. All patients reported a decrease in bone pain after pamidronate 
administration (Table); however most (6/7) patients reported relapses before a new 
cycle of the drug was administered.
At baseline, the bone mineral metabolism parameters (serum calcium, 
25-hydroxyvitamin D, phosphate, and creatinine; total alkaline phosphatase; and 
urinary calcium, phosphorus, and creatinine) were within the reference range, except 
for bone turnover markers (BALP and urinary CTX-I) (Table). Tubular phosphate wast-
ing was not observed in any patient. Fractional excretion of phosphorus was calculated 
based on the assumption that in FDa renal phosphate, wasting might occur even though 
the serum phosphate concentration is in the low normal range. As described for bone 
pain, the concentrations of bone turnover markers also varied with the pamidronate 
cycles and were often found to be higher closer to the next administration (Figure 1). 
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Table. Clinical characteristics of patients with fibrous dysplasia treated with IV pamidronate.
Characteristic P1 P2 P3 P4 P5 P6 P7
Sex F M F F F M F
Age at the end 
of follow-up, y 22 27 27 32 43 28 24
Diagnosis MCA MCA MCA PFD MCA PFD MCA
Location Skull, humerus,  Pelvis Skull, scapula, Humerus, Skull, Skull, ribs, Tibia,  
 ulna, radius,  femur, humerus, radius, radius humerus, tibia, femur, 
 femur, tibia fibula,  ribs, vertebrae,  radius, ulna, pelvis, pelvis, 
  skull, ribs clavicle, hands  femur, pelvis, humerus, sternum 
     tibia, hands feet 
Previous fractures Yes No Yes Yes Yes No Yes
Bone pain at baseline* Moderate Mild Moderate Moderate Severe Moderate Severe
Bone pain at the 
end of follow-up* Asymptomatic Asymptomatic Mild Mild Mild Mild Asymptomatic
Café au lait spots No Yes No No Yes No No
Associated Precocious Acromegaly Precocious None Precocious None Precocious 
endocrinopathy puberty  puberty  puberty  puberty
Cumulative dose of 
pamidronate, mg 1140 1080 1080 1100 3060 2520 1980
Duration of treatment, y 6.83 4.67 3.70 8.10 7.00 7.25 10.92
BALP, IU/L†       
  Baseline 160 172 255 417 3546 512 183
  Final 64 59 110 226 995 385 92
CTX-I, μg/mmo 
creatinine‡       
  Baseline 1270 NA NA 662 1450 1057 197
  Final 510 NA NA 106 995 NA NA
P = patient; F = female; M = male; MCA = McCune-Albright syndrome; PFD = polyostotic fibrous dysplasia; BALP = serum bone alkaline phosphatase; 
CTX-I = urinary C-terminal cross-linking telopeptide of type I collagen; NA = not available.
* Bone pain scale: severe = unbearable or continuous bone pain with or without impaired mobility; moderate = bearable bone pain and/or impaired 
mobility; mild = intermittent episodes of bone pain without impaired mobility; and asymptomatic = no bone pain or altered mobility.
†  Normal range = 31 to 95 IU/L.
‡  Normal range = 10 to 400 μg/mmol creatinine.
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Figure 1.  Individual values of serum bone alkaline phosphatase (BALP) activity in 7 patients with polyostotic fibrous dysplasia 
treated with IV pamidronate. Arrows indicate a cycle of 180 mg of pamidronate.
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Figure 1  (continued). Individual values of serum bone alkaline phosphatase (BALP) activity in 7 patients with polyostotic fibrous 
dysplasia treated with IV pamidronate. Arrows indicate a cycle of 180 mg of pamidronate.
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These observations served as the rationale for adjusting the interval between pamidro- 
nate cycles for each patient individually. These intervals ranged from 2 to 20 months. The 
mean (SD) final cumulative dose of pamidronate was 1709 (821) mg.
Figure 1 shows BALP concentration and pamidronate treatment cycles in each 
patient. BALP concentration decreased after the first pamidronate cycle in all patients 
(from 160 to 102 IU/L, from 172 to 70 IU/L, from 255 to 137 IU/L, from 417 to 
39 IU/L, from 3546 to 2920 IU/L, from 512 to 432 IU/L, and from 183 to 160 IU/L 
for patients 1 to 7, respectively). Although BALP concentrations increased between 
cycles in some cases, continuous pamidronate treatment was associated with numeri-
cally decreased BALP concentration in all patients. Moreover, mean (SD) BALP con-
centrations were significantly lower at the end of follow-up compared with baseline 
in all patients (Table) (749 [1240] vs 276 [338] IU/L; P < 0.02). BALP concentra-
tions decreased to normal values (31–95 IU/L) in 3 patients.
Baseline and final urinary CTX-I concentrations were determined in 3 patients, 
but the decrease (56%) was not statistically significant. At the end of follow-up, the 
urine CTX-I concentration was within the normal range (10–400 μg/mmol creati-
nine) in 1 patient (Table).
Thirteen FDas were analyzed—2 in patients 6, 7, and 4; 3 in patient 5; and 4 in 
patient 1. After the first 2 years of pamidronate treatment, the absolute BMD value 
increased in 9 of the 13 evaluated FDas. Individual values are shown in Figure 2. 
The mean (SD) BMD of the FDas was 5.9% higher at 12 months (0.929 [0.240] vs 
0.981 [0.249] g/cm2; P < 0.05) and 7.3% higher at 24 months (0.929 [0.240] vs 
0.995 [0.277] g/cm2; P = NS) compared with baseline. It is possible that statistically 
significant differences were not observed at 24 months due to a higher dispersion of 
values resulting from individual responses to treatment. The BMD of the CLas 
showed no significant changes from baseline values (1.104 [0.211] g/cm2), a change 
of 0.20% at 12 months (1.106 [0.234] g/cm2), and a change of –0.02% at 24 months 
(1.099 [0.209] g/cm2). FDa BMD had a mean of 15.3% lower than the corresponding 
CLa values at baseline. Pamidronate treatment was associated with changes from base-
line in the difference in BMD between FDa and CLa of 10.8% after 12 months (P = 
NS) and 9.3% after 24 months (P < 0.05). BMD analysis found that the response to 
treatment was not uniform among patients (Figure 2) or when comparing different 
affected areas in a single patient (eg, patients 1 and 5).
In these patients, evidence of refilling of osteolytic areas was not found. Two pa-
tients reported transient flulike symptoms after the first pamidronate cycle. No other 
adverse events were reported.
DISCUSSION
FD of bone is a rare disease for which definitive treatment has not been found.9 Since 
initial evidence reporting beneficial effects of IV pamidronate treatment in patients 
with FD,1 several authors have described the clinical outcome and radiographic, bio-
chemical, and densitometric findings in these patients.2–18 Based on a literature search 
using the PubMed and Current Contents databases, only the large series of patients 
studied by Chapurlat et al2,8,9 described >3 years of follow-up in adult patients with 
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FD who were treated with pamidronate. As described by Chapurlat,9 treatment with 
pamidronate has been found to be well tolerated, reduce increased osteoclastic activity 
in FD, and probably improve bone pain, but further randomized controlled trials are 
needed.
The present case series summarized clinical outcome and bone turnover throughout 
~7 years of treatment with IV pamidronate in young adults with polyostotic FD. 
Pamidronate treatment was associated with different outcomes in different patients. 
Biochemical findings served as rationale for lengthening or shortening the interval 
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Figure 2.  Bone mineral density (BMD) values of fibrous dysplasia areas in 5 patients (p) 
(p 1, 4, 5, 6, and 7) treated with IV pamidronate. Each line corresponds to 
1 measured fibrous dysplasia area. Solid lines depict BMD increases (9 of 
13 evaluated areas) and dashed lines depict BMD reductions.
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between pamidronate cycles. Long-term individualized pamidronate treatment was 
found to reduce bone pain and bone turnover.
Unlike some patients with other bone diseases, such as Paget’s disease, this group 
of patients with FD showed no apparent resistance to pamidronate treatment.24
Our long-term clinical and biochemical observations are in agreement with those 
recently reported by Chapurlat et al.8,9 In contrast, however, we did not find conclu-
sive radiographic evidence of improvement. It was not the purpose of this study to 
analyze the pathophysiologic mechanism that would account for these different 
findings.
In an analysis in 199 patients who did not receive pamidronate treatment, Hart et 
al25 postulated that a plateau in FD lesions occurs between the ages of 20 and 30 years, 
as the natural history of the disease. This analysis was based on bone scintigraphy 
determinations; unfortunately, it did not include biochemical determination of bone 
turnover markers. It is possible that even though progression of the disease may reach 
a plateau in the third decade of life, already existing lesions would still be active, as 
evidenced by the increase in bone turnover marker concentrations and bone pain ob-
served in the patients in the present analysis and by their decrease after each course of 
pamidronate treatment.
An increase in BMD of the FDas was seen after pamidronate treatment. However, 
BMD analysis also found that the response to treatment was not uniform among patients 
or when comparing different affected areas in a single patient (eg, patients 1 and 5).
Limitations
This study had several limitations, including the small case series, absence of a 
comparison group of patients with untreated FD, subjectivity of bone pain assess-
ment, variable duration of follow-up, and incompleteness of BMD and CTX-I assess-
ments. In addition, adherence to calcium and vitamin D was not monitored and ad-
verse events were not detailed. However, we observed clinical improvement after 
long-term IV pamidronate treatment.
CONCLUSIONS
In this small group of patients with FD receiving long-term treatment with IV 
pamidronate, improvements in bone pain and BMD were observed. However, blinded 
controlled trials are needed to confirm the effectiveness of individualized pamidronate 
administration in the long-term treatment of adult patients with FD.
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